MetLife, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +40

MetLife, Inc. (MET): Is This a Good Health Insurance Stock to Buy Now?

AI-generated analysis

📈 MetLife reported a 20% year-over-year rise in adjusted earnings to $1.3 billion ($1.83 per share) for Q1 2024.

💰 The company increased its share repurchase authorization to $3 billion following a strong first quarter performance.

📊 Adjusted premium fees and other revenues grew by 4% year-over-year, totaling $12 billion in the first quarter.

⚠️ Piper Sandler lowered its price target on MetLife shares from $85 to $82 due to increased Group Benefits claims in dental.

🏆 Hedge fund sentiment is positive with 36 funds holding significant stakes, led by Pzena Investment Management.

🌍 MetLife serves over 90 million customers across more than 60 countries as a major global insurer.

📉 Analyst Piper Sandler maintains an Overweight rating despite the price target reduction following earnings.

Bullish Signals
  • MetLife achieved a substantial 20% year-over-year increase in adjusted earnings, reaching $1.3 billion for Q1 2024.
  • The company successfully increased its share repurchase authorization to $3 billion, signaling confidence in its capital position.
  • Adjusted premium fees and other revenues grew by 4% year-over-year to reach $12 billion in the first quarter.
  • Hedge fund sentiment remains robust with 36 funds holding significant stakes in MetLife as of Q1 2024.
Risk Factors
  • Piper Sandler lowered its price target on MetLife shares from $85 to $82 following an increase in Group Benefits claims, particularly in dental.
Full Analysis
MetLife Inc. (NYSE:MET) recently reported a strong first quarter of 2024, with adjusted earnings rising 20% year-over-year to $1.3 billion, or $1.83 per share. The company also increased its share repurchase authorization to $3 billion and saw adjusted premium fees and other revenues grow by 4% to $12 billion compared to the same quarter last year. Despite these positive earnings results, analyst Piper Sandler lowered its price target on MetLife shares from $85 to $82 while maintaining an Overweight rating. The downgrade was driven by increased Group Benefits claims, specifically in dental coverage, a trend observed across the industry during this earnings season. However, Piper Sandler noted that excluding these specific claims, MetLife's earnings remained consistent with prior projections. MetLife serves over 90 million customers across more than 60 countries as one of the world's largest providers of insurance and annuities. Hedge fund sentiment remains positive, with 36 funds holding significant stakes in the company as of Q1 2024, led by Pzena Investment Management. The article ranks MetLife 10th on a list of best health insurance stocks to buy, though the author suggests AI stocks may offer higher returns.